RaQualia Pharma Inc. (4579.T)
JPY 337.0
(0.9%)
JPY 337.0
(0.9%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.39 Billion JPY | 1.62% |
| 2022 | -3.45 Billion JPY | -49.73% |
| 2021 | -2.3 Billion JPY | -71.01% |
| 2020 | -1.34 Billion JPY | 37.9% |
| 2019 | -2.17 Billion JPY | -30.19% |
| 2018 | -1.66 Billion JPY | 26.45% |
| 2017 | -2.26 Billion JPY | -58.85% |
| 2016 | -1.42 Billion JPY | 22.41% |
| 2015 | -1.84 Billion JPY | -4.33% |
| 2014 | -1.76 Billion JPY | 56.29% |
| 2013 | -4.03 Billion JPY | 17.48% |
| 2012 | -4.88 Billion JPY | 36.26% |
| 2011 | -7.67 Billion JPY | -126.14% |
| 2010 | -3.39 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 869.24 Million JPY | 125.59% |
| 2024 Q2 | 641.57 Million JPY | -37.7% |
| 2023 Q2 | -3.29 Billion JPY | 17.75% |
| 2023 FY | -3.39 Billion JPY | 1.62% |
| 2023 Q4 | -3.39 Billion JPY | 6.73% |
| 2023 Q3 | -3.64 Billion JPY | -10.41% |
| 2023 Q1 | -4.01 Billion JPY | -16.15% |
| 2022 Q1 | -2.26 Billion JPY | 1.83% |
| 2022 Q2 | -2.91 Billion JPY | -28.71% |
| 2022 Q4 | -3.45 Billion JPY | -4.26% |
| 2022 FY | -3.45 Billion JPY | -49.73% |
| 2022 Q3 | -3.31 Billion JPY | -13.66% |
| 2021 FY | -2.3 Billion JPY | -71.01% |
| 2021 Q1 | -1.98 Billion JPY | -47.01% |
| 2021 Q2 | -1.98 Billion JPY | -0.19% |
| 2021 Q3 | -2.49 Billion JPY | -25.83% |
| 2021 Q4 | -2.3 Billion JPY | 7.73% |
| 2020 Q4 | -1.34 Billion JPY | 19.45% |
| 2020 Q2 | -1.78 Billion JPY | 15.65% |
| 2020 FY | -1.34 Billion JPY | 37.9% |
| 2020 Q1 | -2.11 Billion JPY | 2.4% |
| 2020 Q3 | -1.67 Billion JPY | 6.36% |
| 2019 Q1 | -1.3 Billion JPY | 21.83% |
| 2019 Q2 | -1.92 Billion JPY | -47.98% |
| 2019 Q3 | -1.77 Billion JPY | 8.04% |
| 2019 Q4 | -2.17 Billion JPY | -22.39% |
| 2019 FY | -2.17 Billion JPY | -30.19% |
| 2018 Q3 | -2.01 Billion JPY | -3.74% |
| 2018 Q2 | -1.94 Billion JPY | -0.2% |
| 2018 Q4 | -1.66 Billion JPY | 17.28% |
| 2018 FY | -1.66 Billion JPY | 26.45% |
| 2018 Q1 | -1.94 Billion JPY | 14.46% |
| 2017 Q2 | -1.9 Billion JPY | -68.37% |
| 2017 FY | -2.26 Billion JPY | -58.85% |
| 2017 Q4 | -2.26 Billion JPY | -33.83% |
| 2017 Q3 | -1.69 Billion JPY | 10.81% |
| 2017 Q1 | -1.12 Billion JPY | 20.96% |
| 2016 FY | -1.42 Billion JPY | 22.41% |
| 2016 Q1 | -1.04 Billion JPY | 43.14% |
| 2016 Q2 | -1.14 Billion JPY | -9.29% |
| 2016 Q3 | -1.37 Billion JPY | -20.6% |
| 2016 Q4 | -1.42 Billion JPY | -3.53% |
| 2015 FY | -1.84 Billion JPY | -4.33% |
| 2015 Q1 | -976.9 Million JPY | 44.62% |
| 2015 Q2 | -996.77 Million JPY | -2.03% |
| 2015 Q4 | -1.84 Billion JPY | -63.3% |
| 2015 Q3 | -1.12 Billion JPY | -13.06% |
| 2014 FY | -1.76 Billion JPY | 56.29% |
| 2014 Q3 | -2.83 Billion JPY | 10.19% |
| 2014 Q4 | -1.76 Billion JPY | 37.79% |
| 2014 Q2 | -3.15 Billion JPY | 39.8% |
| 2014 Q1 | -5.24 Billion JPY | -29.97% |
| 2013 Q3 | -3.54 Billion JPY | 4.54% |
| 2013 Q1 | -4.28 Billion JPY | 12.37% |
| 2013 FY | -4.03 Billion JPY | 17.48% |
| 2013 Q2 | -3.71 Billion JPY | 13.42% |
| 2013 Q4 | -4.03 Billion JPY | -13.93% |
| 2012 Q4 | -4.88 Billion JPY | 11.99% |
| 2012 Q1 | -4.84 Billion JPY | 36.91% |
| 2012 Q3 | -5.55 Billion JPY | 11.96% |
| 2012 Q2 | -6.31 Billion JPY | -30.36% |
| 2012 FY | -4.88 Billion JPY | 36.26% |
| 2011 Q4 | -7.67 Billion JPY | -28.57% |
| 2011 Q3 | -5.96 Billion JPY | -105.09% |
| 2011 Q2 | -2.9 Billion JPY | 0.0% |
| 2011 FY | -7.67 Billion JPY | -126.14% |
| 2010 FY | -3.39 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 557.352% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | -199.576% |
| GNI Group Ltd. | -17.93 Billion JPY | 81.058% |
| Linical Co., Ltd. | -4.46 Billion JPY | 23.89% |
| Trans Genic Inc. | -221.16 Million JPY | -1435.939% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 22.69% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 29.081% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 336.968% |
| AnGes, Inc. | -3.79 Billion JPY | 10.552% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -707.263% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 113.638% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -581.922% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -628.432% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | -25.531% |
| CanBas Co., Ltd. | -1.88 Billion JPY | -79.908% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -245.879% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -228.356% |
| Kidswell Bio Corporation | 343.58 Million JPY | 1088.687% |
| PeptiDream Inc. | 3.29 Billion JPY | 203.19% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -249.275% |
| Ribomic Inc. | -2.09 Billion JPY | -61.783% |
| SanBio Company Limited | -3.78 Billion JPY | 10.362% |
| Healios K.K. | -2.19 Billion JPY | -55.115% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -259.526% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | -29.452% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | -139.723% |
| StemRIM | -8.41 Billion JPY | 59.607% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 27.468% |
| FunPep Company Limited | -1.79 Billion JPY | -89.42% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | -59.0% |
| Stella Pharma Corporation | -1.11 Billion JPY | -203.467% |
| TMS Co., Ltd. | -3.44 Billion JPY | 1.439% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 38.855% |
| Cuorips Inc. | -5.56 Billion JPY | 38.914% |
| K Pharma,Inc. | -3.26 Billion JPY | -3.999% |
| Takara Bio Inc. | -32.2 Billion JPY | 89.451% |
| ReproCELL Incorporated | -2.93 Billion JPY | -15.582% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -413.952% |
| StemCell Institute Inc. | -2.83 Billion JPY | -19.75% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | -64.398% |
| CellSeed Inc. | -2.01 Billion JPY | -68.834% |